Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses through registrational studies. Gilead retains global commercialization rights and will pay Galapagos 20-23% royalties on net sales.

Cormorant Asset Management sold its entire $63.63 million stake in Arcellx (775,000 shares) in Q4, completely exiting a position that represented 4.4% of its AUM. The exit proved poorly timed, as Arcellx shares surged following Gilead Sciences' takeover announcement valuing the company at $7.8 billion with an offer of $115 per share plus potential milestone payments. Arcellx shares are up 80% this year, significantly outperforming the S&P 500.

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Gilead Sciences agreed to acquire Arcellx for $7.8 billion, or $115 per share in cash, plus a $5-per-share contingent value right. The acquisition strengthens Gilead's oncology portfolio by adding anito-cel, a CAR T-cell therapy for multiple myeloma with promising clinical results. Arcellx shares rose on the news and are trading near their 52-week highs.

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. The investigations concern Arcellx's $115 per share sale to Gilead Sciences, Enhabit's $13.80 per share sale to Kinderhook Industries, and Veris Residential's $19 per share sale to an Affinius Capital-led consortium. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Gilead Sciences announced a definitive agreement to acquire biotechnology company Arcellx for approximately $7.8 billion ($115 per share in cash), representing a 68% premium to Arcellx's 30-day volume-weighted average price. The deal includes a contingent value right of $5 per share if anito-cel, Arcellx's lead CAR-T therapy, reaches $6 billion in cumulative global net sales by end of 2029. The acquisition is expected to close in Q2 2026 and expands Gilead's existing collaboration with Arcellx on the investigational BCMA-directed CAR-T cell therapy for multiple myeloma.

Gilead Sciences announced the acquisition of Arcellx for $115 per share in cash plus a $5 per share contingent value right, totaling $7.8 billion in implied equity value. The deal aims to accelerate development and commercialization of anito-cel, a CAR T-cell therapy for relapsed or refractory multiple myeloma, with FDA approval anticipated by December 2026. The transaction is expected to be accretive to Gilead's earnings per share starting in 2028.

The CAR T-cell therapy market for multiple myeloma is expected to grow significantly by 2034, driven by extensive R&D activities, emerging therapies targeting BCMA, and increasing multiple myeloma incidence rates.

The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.